<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d478">
    <sentence id="DDI-DrugBank.d478.s0" text="Ergot-containing drugs have been reported to cause prolonged vasospastic reactions.">
        <entity id="DDI-DrugBank.d478.s0.e0" charOffset="0-4"
            type="group" text="Ergot"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s1" text="Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.">
        <entity id="DDI-DrugBank.d478.s1.e0" charOffset="80-89"
            type="drug" text="ergotamine"/>
        <entity id="DDI-DrugBank.d478.s1.e1" charOffset="105-126"
            type="group" text="ergot-type medications"/>
        <entity id="DDI-DrugBank.d478.s1.e2" charOffset="134-150"
            type="drug" text="dihydroergotamine"/>
        <entity id="DDI-DrugBank.d478.s1.e3" charOffset="155-166"
            type="drug" text="methysergide"/>
        <entity id="DDI-DrugBank.d478.s1.e4" charOffset="173-183"
            type="drug" text="naratriptan"/>
        <ddi id="DDI-DrugBank.d478.s1.d0" e1="DDI-DrugBank.d478.s1.e0"
            e2="DDI-DrugBank.d478.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d478.s1.d1" e1="DDI-DrugBank.d478.s1.e1"
            e2="DDI-DrugBank.d478.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d478.s1.d2" e1="DDI-DrugBank.d478.s1.e2"
            e2="DDI-DrugBank.d478.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d478.s1.d3" e1="DDI-DrugBank.d478.s1.e3"
            e2="DDI-DrugBank.d478.s1.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s2" text="The administration of naratriptan with other 5-HT1 agonists has not been evaluated in migraine patients.">
        <entity id="DDI-DrugBank.d478.s2.e0" charOffset="22-32"
            type="drug" text="naratriptan"/>
        <entity id="DDI-DrugBank.d478.s2.e1" charOffset="45-58"
            type="group" text="5-HT1 agonists"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s3" text="Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.">
        <entity id="DDI-DrugBank.d478.s3.e0" charOffset="71-81"
            type="drug" text="naratriptan"/>
        <entity id="DDI-DrugBank.d478.s3.e1" charOffset="93-106"
            type="group" text="5-HT1 agonists"/>
        <ddi id="DDI-DrugBank.d478.s3.d0" e1="DDI-DrugBank.d478.s3.e0"
            e2="DDI-DrugBank.d478.s3.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s4" text="Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.">
        <entity id="DDI-DrugBank.d478.s4.e0" charOffset="0-38"
            type="group" text="Selective serotonin reuptake inhibitors"/>
        <entity id="DDI-DrugBank.d478.s4.e1" charOffset="41-45"
            type="group" text="SSRIs"/>
        <entity id="DDI-DrugBank.d478.s4.e2" charOffset="55-64"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d478.s4.e3" charOffset="67-77"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d478.s4.e4" charOffset="80-89"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d478.s4.e5" charOffset="92-101"
            type="drug" text="sertraline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s5" text="If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.">
        <entity id="DDI-DrugBank.d478.s5.e0" charOffset="30-40"
            type="drug" text="naratriptan"/>
        <entity id="DDI-DrugBank.d478.s5.e1" charOffset="49-52"
            type="group" text="SSRI"/>
        <ddi id="DDI-DrugBank.d478.s5.d0" e1="DDI-DrugBank.d478.s5.e0"
            e2="DDI-DrugBank.d478.s5.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s6" text="Drug/ Laboratory Test Interactions AMERGE Tablets are not known to interfere with commonly employed clinical laboratory tests.">
        <entity id="DDI-DrugBank.d478.s6.e0" charOffset="35-40"
            type="brand" text="AMERGE"/>
    </sentence>
</document>
